Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion

The Johns Hopkins hospital experience

Eric M. Aldrich, Andrew W. Lee, Celia S. Chen, Rebecca F Gottesman, Mona Bahouth, Philippe Gailloud, Kieran Murphy, Robert Wityk, Neil R Miller

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND PURPOSE: Central retinal artery occlusion results in acute visual loss with poor spontaneous recovery. Current standard therapies do not alter the natural history of disease. Several open-label clinical studies using continuous infusion of thrombolytic agents have suggested that local intraarterial fibrinolysis (LIF) is efficacious in the treatment of central retinal artery occlusion. The aim is to compare the visual outcome in patients with acute central retinal artery occlusion of presumed thromboembolic etiology treated with LIF administered in aliquots with that of patients treated with standard therapy. METHODS: We conducted a single-center, nonrandomized interventional study of consecutive patients with acute central retinal artery occlusion from July 1999 to July 2006. RESULTS: Twenty-one patients received LIF and 21 received standard therapy. Seventy-six percent of subjects in the LIF group had a visual acuity improvement of one line or more compared with 33% in the standard therapy group (P≤0.012, Fisher exact). Multivariate logistic regression controlling for gender, history of prior stroke/transient ischemic attack, and history of hypercholesterolemia showed that patients who received tissue plasminogen activator were 36 times more likely to have improvement in visual acuity (P≤0.0001) after adjusting for these covariates. Post hoc analysis showed that patients who received tissue plasminogen activator were 13 times more likely to have improvement in visual acuity of 3 lines or more (P≤0.03) and 4.9 times more likely to have a final visual acuity of 20/200 or better (P≤0.04). Two groin hematomas were documented in the LIF group. No ischemic strokes, retinal or intracerebral hemorrhages were documented. CONCLUSIONS: LIF administered in aliquots is associated with an improvement in visual acuity compared with standard therapy and has few side effects.

Original languageEnglish (US)
Pages (from-to)1746-1750
Number of pages5
JournalStroke
Volume39
Issue number6
DOIs
StatePublished - Jun 1 2008

Fingerprint

Retinal Artery Occlusion
Fibrinolysis
Visual Acuity
Tissue Plasminogen Activator
Therapeutics
Stroke
Retinal Hemorrhage
Fibrinolytic Agents
Groin
Transient Ischemic Attack
Cerebral Hemorrhage
Group Psychotherapy
Hypercholesterolemia
Hematoma
Logistic Models

Keywords

  • Retinal artery occlusion
  • Thrombolytic therapy
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing
  • Medicine(all)

Cite this

Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion : The Johns Hopkins hospital experience. / Aldrich, Eric M.; Lee, Andrew W.; Chen, Celia S.; Gottesman, Rebecca F; Bahouth, Mona; Gailloud, Philippe; Murphy, Kieran; Wityk, Robert; Miller, Neil R.

In: Stroke, Vol. 39, No. 6, 01.06.2008, p. 1746-1750.

Research output: Contribution to journalArticle

@article{ce8401ef92d74780ae5eed8dbf32d51c,
title = "Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: The Johns Hopkins hospital experience",
abstract = "BACKGROUND AND PURPOSE: Central retinal artery occlusion results in acute visual loss with poor spontaneous recovery. Current standard therapies do not alter the natural history of disease. Several open-label clinical studies using continuous infusion of thrombolytic agents have suggested that local intraarterial fibrinolysis (LIF) is efficacious in the treatment of central retinal artery occlusion. The aim is to compare the visual outcome in patients with acute central retinal artery occlusion of presumed thromboembolic etiology treated with LIF administered in aliquots with that of patients treated with standard therapy. METHODS: We conducted a single-center, nonrandomized interventional study of consecutive patients with acute central retinal artery occlusion from July 1999 to July 2006. RESULTS: Twenty-one patients received LIF and 21 received standard therapy. Seventy-six percent of subjects in the LIF group had a visual acuity improvement of one line or more compared with 33{\%} in the standard therapy group (P≤0.012, Fisher exact). Multivariate logistic regression controlling for gender, history of prior stroke/transient ischemic attack, and history of hypercholesterolemia showed that patients who received tissue plasminogen activator were 36 times more likely to have improvement in visual acuity (P≤0.0001) after adjusting for these covariates. Post hoc analysis showed that patients who received tissue plasminogen activator were 13 times more likely to have improvement in visual acuity of 3 lines or more (P≤0.03) and 4.9 times more likely to have a final visual acuity of 20/200 or better (P≤0.04). Two groin hematomas were documented in the LIF group. No ischemic strokes, retinal or intracerebral hemorrhages were documented. CONCLUSIONS: LIF administered in aliquots is associated with an improvement in visual acuity compared with standard therapy and has few side effects.",
keywords = "Retinal artery occlusion, Thrombolytic therapy, Tissue plasminogen activator",
author = "Aldrich, {Eric M.} and Lee, {Andrew W.} and Chen, {Celia S.} and Gottesman, {Rebecca F} and Mona Bahouth and Philippe Gailloud and Kieran Murphy and Robert Wityk and Miller, {Neil R}",
year = "2008",
month = "6",
day = "1",
doi = "10.1161/STROKEAHA.107.505404",
language = "English (US)",
volume = "39",
pages = "1746--1750",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion

T2 - The Johns Hopkins hospital experience

AU - Aldrich, Eric M.

AU - Lee, Andrew W.

AU - Chen, Celia S.

AU - Gottesman, Rebecca F

AU - Bahouth, Mona

AU - Gailloud, Philippe

AU - Murphy, Kieran

AU - Wityk, Robert

AU - Miller, Neil R

PY - 2008/6/1

Y1 - 2008/6/1

N2 - BACKGROUND AND PURPOSE: Central retinal artery occlusion results in acute visual loss with poor spontaneous recovery. Current standard therapies do not alter the natural history of disease. Several open-label clinical studies using continuous infusion of thrombolytic agents have suggested that local intraarterial fibrinolysis (LIF) is efficacious in the treatment of central retinal artery occlusion. The aim is to compare the visual outcome in patients with acute central retinal artery occlusion of presumed thromboembolic etiology treated with LIF administered in aliquots with that of patients treated with standard therapy. METHODS: We conducted a single-center, nonrandomized interventional study of consecutive patients with acute central retinal artery occlusion from July 1999 to July 2006. RESULTS: Twenty-one patients received LIF and 21 received standard therapy. Seventy-six percent of subjects in the LIF group had a visual acuity improvement of one line or more compared with 33% in the standard therapy group (P≤0.012, Fisher exact). Multivariate logistic regression controlling for gender, history of prior stroke/transient ischemic attack, and history of hypercholesterolemia showed that patients who received tissue plasminogen activator were 36 times more likely to have improvement in visual acuity (P≤0.0001) after adjusting for these covariates. Post hoc analysis showed that patients who received tissue plasminogen activator were 13 times more likely to have improvement in visual acuity of 3 lines or more (P≤0.03) and 4.9 times more likely to have a final visual acuity of 20/200 or better (P≤0.04). Two groin hematomas were documented in the LIF group. No ischemic strokes, retinal or intracerebral hemorrhages were documented. CONCLUSIONS: LIF administered in aliquots is associated with an improvement in visual acuity compared with standard therapy and has few side effects.

AB - BACKGROUND AND PURPOSE: Central retinal artery occlusion results in acute visual loss with poor spontaneous recovery. Current standard therapies do not alter the natural history of disease. Several open-label clinical studies using continuous infusion of thrombolytic agents have suggested that local intraarterial fibrinolysis (LIF) is efficacious in the treatment of central retinal artery occlusion. The aim is to compare the visual outcome in patients with acute central retinal artery occlusion of presumed thromboembolic etiology treated with LIF administered in aliquots with that of patients treated with standard therapy. METHODS: We conducted a single-center, nonrandomized interventional study of consecutive patients with acute central retinal artery occlusion from July 1999 to July 2006. RESULTS: Twenty-one patients received LIF and 21 received standard therapy. Seventy-six percent of subjects in the LIF group had a visual acuity improvement of one line or more compared with 33% in the standard therapy group (P≤0.012, Fisher exact). Multivariate logistic regression controlling for gender, history of prior stroke/transient ischemic attack, and history of hypercholesterolemia showed that patients who received tissue plasminogen activator were 36 times more likely to have improvement in visual acuity (P≤0.0001) after adjusting for these covariates. Post hoc analysis showed that patients who received tissue plasminogen activator were 13 times more likely to have improvement in visual acuity of 3 lines or more (P≤0.03) and 4.9 times more likely to have a final visual acuity of 20/200 or better (P≤0.04). Two groin hematomas were documented in the LIF group. No ischemic strokes, retinal or intracerebral hemorrhages were documented. CONCLUSIONS: LIF administered in aliquots is associated with an improvement in visual acuity compared with standard therapy and has few side effects.

KW - Retinal artery occlusion

KW - Thrombolytic therapy

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=46249130850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249130850&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.107.505404

DO - 10.1161/STROKEAHA.107.505404

M3 - Article

VL - 39

SP - 1746

EP - 1750

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -